James M Patrick

US Patent:

6967244, Nov 22, 2005

Filed:

May 26, 2000

Appl. No.:

09/580462

Inventors:

Stephen Fox Heinemann - La Jolla CA, US
James Warner Patrick - Houston TX, US
James Richard Boulter - San Diego CA, US
Evan Samuel Deneris - La Jolla CA, US
Keiji Wada - Rockville MD, US
Marc Charles Ballivet - Geneva, CH
Daniel Jay Goldman - Ann Arbor MI, US
John Gerard Connolly - Del Mar CA, US
Robert Michael Duvoisin - Del Mar CA, US
Eden Deer Heinemann - San Luis Obispo CA, US

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C12N015/12

US Classification:

536 235, 435 691, 4352523, 4353201

Abstract:

The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.

US Patent:

50665936, Nov 19, 1991

Filed:

Aug 31, 1987

Appl. No.:

7/091509

Inventors:

James W. Patrick - Solana Beach CA
Stephen F. Heinemann - La Jolla CA
Barbara D. Boss - San Diego CA
W. Maxwell Cowan - Cardiff by the Sea CA

Assignee:

The Salk Insstitute for Biological Studies - San Diego CA

International Classification:

C12N 500
A61K 3514

US Classification:

43524027

Abstract:

A sequence in the coat glycoprotein of rabies virus is identified as the molecular basis for an essential step in the pathogenesis of the virus, the binding of virus to acetylcholine receptor at neuromuscular junctions prior to virus uptake into peripheral nerves. Based on this discovery, synthetic peptide-based, anti-rabies vaccines are prepared. The active ingredient of such vaccines is a synthetic protein, which is a conjugate with an immunogenic carrier protein of a synthetic peptide with a sequence which includes a sequence which is substantially the same as a substantial portion of the sequence of the acetylcholine receptor-binding segment of the rabies virus coat protein. Anti-rabies antisera, and anti-rabies antibodies, are prepared by injecting a mammal with a synthetic protein of the invention in a manner that induces an immune response in the mammal against the synthetic protein. Hybridomas which secrete anti-rabies antibodies, which bind to specific epitopes on or near the acetylcholine receptor binding segment on the rabies virus coat glycoprotein, are prepared with B cells immunized in vitro with a synthetic peptide or synthetic protein of the invention or taken from a mammal inoculated with such a peptide or protein. The anti-rabies vaccines of the invention avoid risks associated with currently available anti-rabies vaccines.

US Patent:

46526293, Mar 24, 1987

Filed:

Jul 3, 1985

Appl. No.:

6/752222

Inventors:

James W. Patrick - Solana Beach CA
Stephen F. Heinemann - La Jolla CA
Barbara D. Boss - San Diego CA
W. Maxwell Cowan - Cardiff by the Sea CA

Assignee:

The Salk Institute for Biological Studies - San Diego CA

International Classification:

C07K 706
C07K 708

US Classification:

530326

Abstract:

A sequence in the coat glycoprotein of rabies virus is identified as the molecular basis for an essential step in the pathogenesis of the virus, the binding of virus to acetylcholine receptor at neuromuscular junctions prior to virus uptake into peripheral nerves. Based on this discovery, synthetic peptide-based, anti-rabies vaccines are prepared. The active ingredient of such vaccines is a synthetic protein, which is a conjugate with an immunogenic carrier protein of a synthetic peptide with a sequence which includes a sequence which is substantially the same as a substantial portion of the sequence of the acetylcholine receptor-binding segment of the rabies virus coat protein. Anti-rabies antisera, and anti-rabies antibodies, are prepared by injecting a mammal with a synthetic protein of the invention in a manner that induces an immune response in the mammal against the synthetic protein. Hybridomas which secrete anti-rabies antibodies, which bind to specific epitopes on or near the acetylcholine receptor binding segment on the rabies virus coat glycoprotein, are prepared with B cells immunized in vitro with a synthetic peptide or synthetic protein of the invention or taken from a mammal inoculated with such a peptide or protein. The anti-rabies vaccines of the invention avoid risks associated with currently available anti-rabies vaccines.

US Patent:

55915906, Jan 7, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/472989

Inventors:

Stephen F. Heinemann - La Jolla CA
James W. Patrick - Houston TX
James R. Boulter - San Diego CA
Evan S. Deneris - La Jolla CA
John G. Connolly - Del Mar CA
Robert M. Duvoisin - Del Mar CA
Eden D. Heinemann - San Luis Obispo CA
Keiji Wada - Rockville MD
Marc C. Ballivet - Geneva, CH
Daniel J. Goldman - Ann Arbor MI

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

G01N 3353

US Classification:

435 71

Abstract:

The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.

US Patent:

53711882, Dec 6, 1994

Filed:

Jun 12, 1992

Appl. No.:

7/898185

Inventors:

Stephen F. Heinemann - La Jolla CA
James W. Patrick - Houston TX
James R. Boulter - San Diego CA
Evan S. Deneris - La Jolla CA
Keiji Wada - Rockville MD
Marc C. Ballivet - Geneva, CH
Daniel J. Goldman - Ann Arbor MI
John G. Connolly - Del Mar CA
Robert M. Duvoisin - Del Mar CA
Eden D. Heinemann - San Luis Obispo CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C07K 1300
C12N 1512

US Classification:

530350

Abstract:

The present invention relates to a family of neuronal nicotinic acetylcholine receptors comprised of neuronal agonist and non-agonist binding subunits, and DNA sequences encoding such subunits. These novel neuronal nicotinic acetylcholine receptor subunits include the agonist binding subunits alpha2, alpha3, alpha4, and alpha5, plus non-agonist binding subunits beta2, beta3 and beta4. Representative cDNA clones that contain the DNA sequences of the invention have been deposited with the American Type Culture Collection for patent purposes.

US Patent:

48659681, Sep 12, 1989

Filed:

Apr 10, 1985

Appl. No.:

6/718724

Inventors:

Leslie E. Orgel - LaJolla CA
James W. Patrick - Solana Beach CA

Assignee:

The Salk Institute for Biological Studies - San Diego CA

International Classification:

C12Q 168
G01N 2726
G01N 2163

US Classification:

435 6

Abstract:

A first mixture is prepared that contains labeled chain fragments which each has a common end adjacent to a primary nucleotide and a termination at a position from the primary through an nth nucleotide, the first mixture containing nucleotide chain fragments of each length from termination at the primary through termination of the nth nucleotide. A second mixture is prepared that contains labeled chain fragments beginning at the common end and terminating at positions from the first through the nth nucleotide, the second mixture containing chain fragments of each length terminating wherever either a first or a second of the four nucleotides occurs. A third mixture is prepared that contains labeled chain fragments beginning at the common end and terminating at a position from the first through the nth nucleotide, the third mixture containing chain fragments of each length terminating wherever the first or a third of the four nucleotide sequences occurs. The chains are electrophoresed with the first mixture as the center lane. This three-lane system provides a unique band pattern for each of the four nucleotides and permits the sequence to be read merely by directly comparing each of the flanking lanes with the fully stepped center lane.

US Patent:

47073560, Nov 17, 1987

Filed:

Dec 12, 1986

Appl. No.:

6/941163

Inventors:

James W. Patrick - Solana Beach CA
Stephen F. Heinemann - La Jolla CA
Barbara D. Boss - San Diego CA
W. Maxwell Cowan - Cardiff by the Sea CA

Assignee:

The Salk Institute for Biological Studies - San Diego CA

International Classification:

A61K 3702

US Classification:

424 88

Abstract:

A sequence in the coat glycoprotein of rabies virus is identified as the molecular basis for an essential step in the pathogenesis of the virus, the binding of virus to acetylcholine receptor at neuromuscular junctions prior to virus uptake into peripheral nerves. Based on this discovery, synthetic peptide-based, anti-rabies vaccines are prepared. The active ingredient of such vaccines is a synthetic protein, which is a conjugate with an immunogenic carrier protein of a synthetic peptide with a sequence which includes a sequence which is substantially the same as a substantial portion of the sequence of the acetylcholine receptor-binding segment of the rabies virus coat protein. Anti-rabies antisera, and anti-rabies antibodies, are prepared by injecting a mammal with a synthetic protein of the invention in a manner that induces an immune response in the mammal against the synthetic protein. Hybridomas which secrete anti-rabies antibodies, which bind to specific epitopes on or near the acetylcholine receptor binding segment on the rabies virus coat glycoprotein, are prepared with B cells immunized in vitro with a synthetic peptide or synthetic protein of the invention or taken from a mammal inoculated with such a peptide or protein. The anti-rabies vaccines of the invention avoid risks associated with currently available anti-rabies vaccines.

US Patent:

54496063, Sep 12, 1995

Filed:

May 6, 1993

Appl. No.:

8/059502

Inventors:

Stephen F. Heinemann - La Jolla CA
Robert M. Duvoisin - Del Mar CA
Evan S. Deneris - La Jolla CA
James W. Patrick - Houston TX

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C12N 1512

US Classification:

435 6

Abstract:

The present invention discloses a new neuronal nicotinic acetylcholine receptor subunit,. beta. 4. The new subunit can form functional combinations with other neuronal nicotinic acetylcholine receptor subunits, including, but not limited to, alpha2, alpha3, alpha4 and beta2. A cDNA clone containing the DNA sequences that encode the novel receptor subunit of the invention has been deposited with the American Type Culture Collection for patent purposes.